Neuronetics' Leadership Overhaul Signals a Drive for Profitability

MALVERN, Pa. – July 20, 2026 – Neuronetics, a key player in the interventional mental health space, has initiated a significant leadership reshuffle, appointing a new Chief Financial Officer with a formidable track record and promoting an internal leader to helm its expanding network of patient clinics. These moves, which also include the departure of its top legal officer, signal a clear and deliberate strategy: to instill rigorous financial discipline and accelerate growth in its direct-to-patient care model, positioning the company for a new phase of operational maturity and, ultimately, profitability.

The Mandate for a Financial Turnaround

At the heart of this strategic realignment is the appointment of Nir Naor as Chief Financial Officer. The move is less a routine hire and more a statement of intent. Neuronetics' President and CEO, Dan Reuvers, noted that Naor "brings the financial discipline and rigor our strategy demands," a sentiment that resonates deeply when examining the company's recent financial performance and Naor's own professional history.

While Neuronetics posted a respectable 8% year-over-year revenue increase to $34.5 million in the first quarter of 2026, it still reported a net loss of $10.8 million. The company has been transparent about its goal to achieve positive cash flow from operations in the second half of the year, a challenging but critical milestone. This is precisely the environment where Naor has previously thrived. During his tenure as CFO at the surgical solutions firm Axogen, he was instrumental in guiding the company to profitability and positive cash flow within a year, a period that also saw its market capitalization triple. His experience extends to orchestrating the successful sale of Arbor Pharmaceuticals to Azurity Pharmaceuticals, demonstrating a sharp acumen for maximizing shareholder value through strategic financial management.

"The opportunity ahead is meaningful," Naor stated, expressing his eagerness to "strengthen the company’s balance sheet, drive greater operating leverage, and convert the business's momentum into durable margins and attractive returns for shareholders." His mandate is clear: to apply the same rigor that proved successful at Axogen and other life sciences firms to Neuronetics' unique, vertically integrated model. To secure his leadership, the company has granted Naor an inducement package of 500,000 restricted stock units vesting over four years, a significant commitment that aligns his success directly with the company's long-term performance and underscores the board's confidence in his ability to deliver.

Doubling Down on Direct Patient Care

Concurrent with the focus on financial health is a renewed push into the company's core growth engine: its direct patient care arm. The promotion of Cory Anderson to Executive Vice President and General Manager of Greenbrook, Neuronetics' network of interventional psychiatry clinics, is a strategic elevation of a key business segment. Anderson, a company veteran with over two decades of medical technology experience, is now tasked with scaling a critical component of the company's future.

The Greenbrook network, acquired to create an integrated system combining Neuronetics' NeuroStar® TMS technology with on-the-ground clinical services, is already a substantial revenue driver. In the first quarter of 2026, U.S. clinic revenue hit $21.5 million, a 15% increase from the prior year. This segment not only provides a direct channel for the company's TMS treatments for depression and OCD but also offers complementary therapies like SPRAVATO® for treatment-resistant depression. Reuvers praised Anderson's "deep knowledge of interventional psychiatry and focus on operational excellence," calling him the "ideal leader to continue advancing our clinic strategy and expanding access to patient care."

This strategic emphasis on the clinic model taps into a powerful trend. The global market for transcranial magnetic stimulation is projected to more than double by 2030, reaching $2.4 billion, fueled by a growing need for effective, non-invasive mental health treatments. By owning the clinics, Neuronetics controls the end-to-end patient experience, a model that offers immense potential for standardizing care and gathering data, but also presents challenges. The integration of lower-margin clinic operations has impacted the company's overall gross margin, a financial puzzle that the combined expertise of Naor and Anderson will now be tasked with solving.

A Strategic Reshuffle for a Competitive Future

Viewed together, the appointment of Naor, the promotion of Anderson, and the departure of Executive Vice President and Chief Legal Officer Andrew Macan paint a picture of a company deliberately retooling its leadership for the next stage of its journey. Reuvers acknowledged Macan's integral role in the company's history and wished him well, marking a respectful transition as the organization sharpens its focus.

This leadership evolution is happening against the backdrop of a vast and growing need. Neuronetics targets an addressable market of nearly 30 million Americans affected by depression and OCD, with millions of them finding traditional medications to be ineffective. Recent wins, such as the expansion of New York State Medicaid coverage for TMS therapy, signal growing institutional acceptance and open new avenues for access.

However, the path forward is not without its hurdles. The company operates in a competitive field with rivals like MagVenture and Brainsway, and must continue to innovate to maintain its leadership position. The first-quarter earnings-per-share miss and ongoing cash burn highlight the urgency behind this strategic pivot. By bringing in a CFO known for engineering profitability and empowering a seasoned executive to scale its direct-care network, Neuronetics is making a calculated bet that operational excellence and financial discipline are the keys to unlocking the full potential of its mission to expand access to life-changing mental health therapies.